Today’s IPO for Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) opened for trading at $24.45 after pricing 8,477,777 Class A common shares at a public offering price of $18.00 per share, before underwriting discounts and commissions.
In addition, Kiniksa has granted the underwriters a 30-day option to purchase up to 1,271,666 additional Class A common shares at the initial public offering price, less underwriting discounts and commissions.
Goldman Sachs & Co. LLC and J.P. Morgan Securities, LLC are acting as joint book-running managers for the offering. JMP Securities LLC and Wedbush Securities Inc. are acting as co-managers for the offering.
Kiniksa is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.